Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma

Molecular and Cellular Endocrinology

Volumn 365, Issue 2, 2013, Pages 212-222

  Vacas, Eva ^a   Bajo, Ana M ^a   Schally, Andrew V ^b,c   Sánchez Chapado, Manuel ^a,d   Prieto, Juan C ^a   Carmena, María J ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Cell adhesion; Cell migration; NF B; Renal cell carcinoma; ROS; VIP

Indexed keywords

BETA CATENIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JV 1 53; PROTEIN P50; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN 165; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY EPITHELIUM; METASTASIS POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION;

ANTINEOPLASTIC AGENTS; BETA CATENIN; CADHERINS; CARCINOMA, RENAL CELL; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NF-KAPPA B P50 SUBUNIT; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84871360982     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.10.021     Document Type: Article

References (50)

1. Arya M., Bott S.R., Shergill I.S., Ahmed H.U., Williamson M., Patel H.R. The metastatic cascade in prostate cancer. Surg. Oncol. 2006, 15:117-128.
2. Banumathy G., Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol. Ther. 2010, 10:658-664.
3. Binker M.G., Binker-Cosen A.A., Richards D., Oliver B., Cosen-Binker L.I. EGF promotes invasion by PANC-1 cells through Rac1/ROS-dependent secretion and activation of MMP-2. Biochem. Biophys. Res. Commun. 2009, 379:445-450.
4. Bourboulia D., Stetler-Stevenson W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Sem. Cancer Biol. 2010, 20:161-168.
5. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
6. Chibber S., Farhan M., Hassan I., Naseem I. Novel aspect of chemophototherapy in treatment of cancer. Tumour Biol. 2012, 33:701-706.
7. Cohen H.T., McGovern F.J. Renal-cell carcinoma. New. Engl. J. Med. 2005, 353:2477-2490.
8. Collado B., Gutiérrez-Cañas I., Rodríguez-Henche N., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul. Pept. 2004, 119:69-75.
9. Collado B., Carmena M.J., Clemente C., Prieto J.C., Bajo A.M. Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model. Peptides 2007, 28:1896-1901.
10. Couvineau A., Laburthe M. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br. J. Pharmacol. 2012, 166:42-50.
11. Esteban M.A., Tran M.G., Harten S.K., Hill P., Castellanos M.C., Chandra A., et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 2006, 66:3567-3575.
12. Evans A.J., Russell R.C., Roche O., Burry T.N., Fish J.E., Chow V.W.K., et al. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and Snail. Mol. Cell. Biol. 2007, 27:157-169.
13. Fernández-Martínez A.B., Collado B., Bajo A.M., Sánchez-Chapado M., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression. Mol. Cell. Endocrinol. 2007, 270:8-16.
14. Fernández-Martínez A.B., Bajo A.M., Sánchez-Chapado M., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. Prostate 2009, 69:774-786.
15. Fernández-Martínez A.B., Bajo A.M., Arenas M.I., Sánchez-Chapado M., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1. Cancer Lett. 2010, 299:11-21.
16. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278:16-27.
17. Gupta S.C., Hevia D., Patchva S., Park B., Koh W., Aggarwal B.B. Upsides and downsides of ROS for cancer: the roles of ROS in tumorigenesis, prevention, and therapy. Antioxid. Redox Signal. 2012, 16:1295-1322.
18. Halbleib J.M., Nelson W.J. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 2006, 20:3199-3214.
19. Jamora C., Fuchs E. Intercellular adhesion, signalling and the cytoskeleton. Nat. Cell. Biol. 2002, 4:E101-108.
20. Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2002, 2:673-682.
21. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 2004, 22:4991-5004.
22. Kim A., Kim M.J., Yang Y., Kim J.W., Yeom Y.I., Lim J.S. Suppression of NFkappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis 2009, 30:927-936.
23. Krishnamachary B., Zagzag D., Nagasawa H., Rainey K., Okuyama H., Baek J.H., et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 2006, 66:2725-2731.
24. Laburthe M., Couvineau A., Tan V. Class II G-protein coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007, 28:1631-1639.
25. Lee K.H., Kim J.R. Reactive oxygen species regulate the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocyte growth factor. Exp. Mol. Med. 2009, 41:180-188.
26. Linehan W.M., Rubin J.S., Bottaro D.P. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int. J. Biochem. Cell Biol. 2009, 41:753-756.
27. Linehan W.M., Bratslavsky G., Pinto P.A., Schmidt L.S., Neckers L., Bottaro D.P., et al. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 2010, 61:329-343.
28. Ljünberg L., Campbell S.C., Cho H.Y., Jackmin D., Lee J.E., Welkert S., Kiemeney L.A. The epidemiology of renal cell carcinoma. Eur. Urol. 2011, 60:615-621.
29. López-Beltrán A., Carrasco J.C., Cheng L., Scarpelli M., Kirkali Z., Montironi R. 2009 update on the classification of renal epithelial tumors in adults. Int. J. Urol. 2009, 16:432-443.
30. Montero A.J., Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011, 71:1385-1396.
31. Nickerson M.L., Jaeger E., Shi Y., Durocher J.A., Mahurkar S., Zaridze D., et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 2008, 14:4726-4734.
32. Noël A., Gilles C., Foidart J.M. Invasion and metastatic dissemination in breast cancer: mechanisms. Rev. Med. Liege 2011, 66:274-278.
33. Oosterwijk E., Rathmell W.K., Junker K., Brannon A.R., Pouliot F., Finley D.S., et al. Basic research in kidney cancer. Eur. Urol. 2011, 60:622-633.
34. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
35. Peruzzi B., Athauda G., Bottaro D.P. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc. Natl. Acad. Sci. USA 2006, 103:14531-14536.
36. Rekasi Z., Varga J.L., Schally A.V., Halmos G., Armatis P., Groot K., et al. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. Endocrinology 2000, 141:2120-2128.
37. Rini B.I., Atkins M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009, 10:992-1000.
38. Sarsour E.H., Kumar M.G., Chaudhuri L., Kalen A.L., Gaswami P.C. Redox control of the cell cycle in health and disease. Antiox. Redox Signal. 2009, 11:2985-3011.
39. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell. Biol. 2004, 5:343-354.
40. Smith D.G., Magwere T., Burchill S.A. Oxidative stress and therapeutic opportunities: focus on the Ewing's sarcoma family of tumors. Expert Rev. Anticancer Ther. 2011, 11:229-249.
41. Sotomayor S., Carmena M.J., Schally A.V., Varga J.L., Sánchez-Chapado M., Prieto J.C., Bajo A.M. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: antagonistic action of an analog of growth-hormone-releasing hormone. Int. J. Oncol. 2007, 31:1223-1230.
42. Tobar N., Villar V., Santibanez J.F. ROS-NFκB mediates TGF-β1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol. Cell. Biochem. 2010, 340:195-202.
43. Vacas E., Fernández-Martínez A.B., Bajo A.M., Sánchez-Chapado M., Schally A.V., Prieto J.C., et al. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation. Biochim. Biophys. Acta 2012, 1823:1676-1685.
44. Valdehita A., Bajo A.M., Fernández-Martínez A.B., Arenas M.I., Vacas E., Valenzuela P., Ruíz-Villaespesa A., Prieto J.C., Carmena M.J. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Peptides 2010, 31:2035-2045.
45. Valdehita A., Carmena M.J., Bajo A.M., Prieto J.C. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol. Cell. Endocrinol. 2012, 348:241-246.
46. Varga J.L., Schally A.V., Csernus V.J., Zarándi M., Halmos G., Groot K., et al. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc. Natl. Acad. Sci. USA 1999, 96:692-697.
47. Verrax J., Beck R., Dejeans N., Glorieux C., Sid B., Pedrosa R.C., et al. Redox-active quinones and ascorbate: an innovative cancer therapy that exploits the vulnerability of cancer cells to oxidative stress. Anticancer Agents Med. Chem. 2011, 11:213-221.
48. Watanabe H. Extracellular matrix-regulation of cancer invasion and metastasis. Gan To Kagaku Ryoho 2010, 37:2058-2061.
49. Welford S.M., Dorie M.J., Li X., Haase V.H., Giaccia A.J. Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress. Mol. Cell. Biol. 2010, 30:4595-4603.
50. Zhang L., Shi J., Feng J., Klocker H., Lee C., Zhang J. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis. 2004, 7:327-332.